Skip to content

COPD

GOLD 2026 (Global Initiative for Chronic Obstructive Lung Disease) is the reference strategy, updated each year. This summary follows the 2026 Pocket Guide.

GOLD 2026

International Current

Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2026 Report (summarised from the Pocket Guide)

Official source

What's new

  • Group E now starts at one moderate or severe exacerbation in the past year.
  • CAT renamed CAAT (Chronic Airways Assessment Test).
  • Biologics for exacerbations with eosinophils ≥300 despite triple therapy: dupilumab (with chronic bronchitis) and mepolizumab.
  • Ensifentrine as an add-on for persistent dyspnoea.
  • RSV vaccine for people with COPD.